Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes

Biochemical Pharmacology

Volumn 53, Issue 2, 1997, Pages 171-178

  Crewe, H Kim ^a   Ellis, S Wynne ^a   Lennard, Martin S ^a   Tucker, Geoffrey T ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

CYP2C9; CYP2D6; CYP3A4; cytochromes P450; human liver microsomes; tamoxifen 4 hydroxylation

Indexed keywords

CYTOCHROME P450 ISOENZYME; KETOCONAZOLE; QUINIDINE; SULFAPHENAZOLE; TAMOXIFEN;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENOTYPE; HUMAN; HUMAN TISSUE; HYDROXYLATION; IN VITRO STUDY; LIVER METABOLISM; LIVER MICROSOME; MALE; PRIORITY JOURNAL;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DEALKYLATION; FEMALE; HUMANS; HYDROXYLATION; MALE; MICROSOMES, LIVER; MIDDLE AGED; MIXED FUNCTION OXYGENASES; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; TAMOXIFEN;

EID: 0031031421     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(96)00650-8     Document Type: Article

References (36)

1. Catherino WH and Jordan VC, A risk-benefit assessment of tamoxifen therapy. Drug Safety 8: 381-397, 1993.
2. Jordan VC, Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer. Annu Rev Pharmacol Toxicol 35: 195-211, 1995.
3. Buckley MT and Goa KL, Tamoxifen: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Clin Pharmacokin 37:451-490, 1989.
4. Lim CK, Yuan Z-X, Lamb JH, White INH, De Matteis F and Smith LL, A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes. Carcinogenesis 15: 589-593, 1994.
5. Jacolot F, Simon I, Dreano I, Beaune P, Riche C and Berthou F, Identification of the cytochrome P450 IIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem Pharmacol 41: 1911-1919, 1991.
6. Mani C, Gelboin HV, Park SS, Pearce R, Parkinson A and Kupfer D, Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P450-catalysed N-demethylation and 4-hydroxylation. Drug Metab Dispos 21: 645-656, 1993.
7. Mani C, Pearce R, Parkinson A and Kupfer D, Involvement of cytochrome P4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes. Carcinogenesis 15: 2715-2720, 1994.
8. Simon I, Berthou F, Riche C, Beaune P and Ratanasavanh D, Both cytochromes P4501A1 and 3A4 are involved in the N-demethylation of tamoxifen. Proceedings of the Fifth European ISSX Meeting, Tours, France, Abstract No. 44, 1993.
9. Daniel PC, Gaskell J, Bishop H, Campbell C and Nicholson R, Determination of tamoxifen and biologically active metabolites in human breast tumour and plasma. Eur J Cancer Clin Oncol 17: 1183-1189, 1981.
10. Jordan VC, Collins MM, Rowsby L and Prestwich G, A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 75: 305-316, 1977.
11. Williams ML, Lennard MS, Martin IJ and Tucker GT, Interindividual variation in the isomerisation of 4-hydroxytamoxifen by human liver microsomes: involvement of cytochromes P450. Carcinogenesis 15: 2733-2738, 1994.
12. Moorthy B, Sriram P, Pathak DN, Bodell WJ and Randerath K, Tamoxifen metabolic activation: comparison of DNA adducts formed by microsomal and chemical activation of tamoxifen and 4-hydroxytamoxifen with DNA adducts formed in vivo. Cancer Res 56: 53-57, 1996.
13. Blankson EA, Ellis SW, Lennard MS, Tucker GT and Rogers K, The metabolism of tamoxifen by human liver microsomes is not mediated by cytochrome P450IID6. Biochem Pharmacol 42: S209-S212, 1991.
14. Styles JA, Davies A, Lim CK, De Matteis F, Stanley LA, White INH, Yuan Z-X and Smith LL, Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochromes P450. Carcinogenesis 15: 5-9, 1994.
15. Daniels L, Blankson EA, Henderson CJ, Harris AR, Wolf CR, Lennard MS and Tucker GT, Delineation of human cytochromes P450 involved in the metabolism of tamoxifen. Br J Clin Pharmacol 34: 153P-154P, 1992.
16. 14C]tamoxifen to liver microsomes and the forms of cytochrome P450 involved. Biochem Pharmacol 49: 1035-1042, 1995.
17. Shaw L, Lennard MS, Tucker GT, Bax NDS and Woods HF, Irreversible binding and metabolism of propranolol by human liver microsomes - relationship to polymorphic oxidation. Biochem Pharmacol 36: 2283-2288, 1987.
18. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ, Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275, 1951.
19. Ellis SW, Hayhurst GP, Smith G, Lightfoot T, Wong MMS, Simula A, Ackland MJ, Sternberg MJE, Lennard MS, Tucker GT and Wolf CR, Evidence that aspartic acid 301 is a critical substrate-contact residue in the active site of cytochrome P450 2D6. J Biol Chem 270: 29055-29058, 1996.
20. Ching MS, Lennard MS, Tucker GT, Woods HF, Kelly DE and Kelly SL, The expression of human cytochrome P450IA1 in the yeast Saccharomyces cerevisiae. Biochem Pharmacol 42: 753-758, 1991.
21. Coleman T, Ellis SW, Martin IJ, Lennard MS and Tucker GT, MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is N-demethylated by CYPs 2D6, 1A2 and 3A4 - implications for Parkinson's disease. J Pharmacol Exp Ther 277: 685-690, 1996.
22. Omura T and Sato R, The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239: 2370-2378, 1964.
23. Otton SV, Crewe HK, Lennard MS, Tucker GT and Woods HF, Use of quinidine inhibition to define the role of the sparteine/debrisoquin cytochrome P450 in metoprolol oxidation by human liver microsomes. J Pharmacol Exp Ther 247: 242-247, 1988.
24. Clarke SE, Ayrton AD and Chenery RJ, Characterisation of the inhibition of P4501A2 by furafylline. Xenobiotica 24: 517-526, 1994.
25. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE and Chenery RJ, Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25: 261-270, 1995.
26. Guengerich FP, Kim D-H and Iwasaki M, Role of human cytochrome P-450IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 4: 168-179, 1991.
27. Sesardic D, Edwards RJ, Davies DS, Thomas PE, Levin W and Boobis AR, High affinity phenacetin O-deethylase activity is catalysed specifically by cytochrome P450d (P4501A2) the liver of rat. Biochem Pharmacol 39: 489-498.
28. Miners JO, Smith KJ, Robson RA, McManus ME, Veronese ME and Birkett DJ, Tolbutamide hydroxylation by human liver microsomes. Biochem Pharmacol 37: 1137-1144, 1988.
29. Meier UT, Dayer P, Male P-J, Kronbach T and Meyer UA, Mephenytoin hydroxylation polymorphism: characterisation of the enzyme deficiency in liver microsomes of poor metabolisers phenotyped in vivo. Clin Pharmacol Ther 38: 488-494, 1985.
30. Peter R, Bocker R, Beaune PH, Iwaski M, Guengerich FP and Yang CS, Hydroxylation of chlorzoxazone as a specific probe cytochrome P-450IIE1. Chem Res Toxicol 3: 566-573, 1990.
31. Waxman DJ, Attisano C, Guengerich JR and Lapenson DP, Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6β-hydroxylase cytochrome P450 enzyme. Arch Biochem Biophys 263: 424-436, 1988.
32. Rowland K, Ellis SW, Lennard MS and Tucker GT, Variable contribution of CYP2D6 to the N-dealkylation of S-(-)-propranolol by human liver microsomes. Br J Clin Pharmacol 42: 394-397, 1996.
33. Ruenitz PC and Toledo MM, Inhibition of rabbit liver microsomal oxidative metabolism and substrate binding by tamoxifen and the geometric isomers of clomiphene. Biochem Pharmacol 29: 1583-1587, 1980.
34. Lodwick R, McConkey B, Brown AM and Beeley L, Life threatening interaction between tamoxifen and warfarin. Br Med J 295: 1141, 1987.
35. Tenni P, Lalaich DL and Byrne MJ, Life threatening interaction between tamoxifen and warfarin. Br Med J 298: 93, 1989.
36. Rettie AE, Korzekwa KR, Kunze KL, Laurence RF, Eddy AC, Ayoma T, Gelboin HV, Gonzalez FJ and Trager WF, Hydroxylation of warfarin by human cDNA expressed cytochrome P450: a role for P4502C9 in the etiology of (S)-warfarin drug interactions. Chem Res Toxicol 5: 54-59, 1992.